MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
public offering...
$18,346K
Proceeds from issuance of
shares, net-Private...
$1,791K
Proceeds from issuance of
shares, net-At Market...
$168K
Net cash provided by
financing activities
$20,305K
Net decrease in cash
$2,993K
Canceled cashflow
$17,312K
Loss on issuance of
warrants
-$75,644K
Change in fair value of
convertible notes
-$22,911K
Loss on derivative
liability
$13,088K
Stock-based compensation
expense
$5,317K
Prepaid expenses and
other current assets
-$1,185K
Non-cash issuance of
common stock
$250K
Depreciation
$78K
Net cash used in
operating activities
-$17,308K
Net cash used in
investing activities
-$4K
Canceled cashflow
$118,473K
Change in fair value of
warrants
-$84,934K
Purchases of property and
equipment
$4K
Net (loss) income
-$39,222K
Accounts payable
-$4,968K
Change in fair value of
contingent consideration
-$3,499K
Accrued expenses and
other liabilities
-$2,206K
Other assets and
liabilities
$952K
Back
Back
Cash Flow
source: myfinsight.com
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)